



Arielle Beauchesne, Pharm.D; Laura Beresford, B.Sc.Pharm, Pharm.D; Roxane Carr, B.Sc.Pharm, Pharm.D; Kendra Sih, B.Sc.Pharm, Pharm.D, ACPR

Background

- Headache is a common reason for children to go to the Emergency Department (ED)
- Evidence supports standard intravenous (IV) therapy with analgesics, dopamine receptor antagonists, and anti-emetics for adults with migraine headache
- Lack of pediatric data or guidelines to direct treatment in children
- Considerations for choice of migraine treatment in children:
- Adverse effects
- Infusion times
- Intravenous propofol, administered at sub-anesthetic doses, has been identified as a possible alternative.
- Pediatric studies with propofol for migraine have shown inconsistent results

Objectives

Primary:

- To compare the difference in ED length of stay (LOS) after initiation of IV abortive therapy between propofol and standard IV therapy
- Secondary:
- To determine the difference between propofol and standard IV therapy in:
 - Proportion of patients achieving pain scores ≤4 on the Numeric Rating Scale (NRS)
- Total ED LOS
- Incidence of rebound migraine headache (proportion of patients returning to the ED for migraine within 24 hours)
- Patient disposition post-ED migraine treatment
- To describe adverse drug events

Methods

- Design: Retrospective matched 2:1 cohort study
- Inclusion: Patients \geq 7 years old presenting to the ED for migraine headache
- Cases: Those who received IV propofol for abortive migraine therapy
- Controls: Those who received 'standard therapy' (IV metoclopramide, ketorolac, and diphenhydramine)
- Exclusion: Presence of head injury, presence of an intracranial shunt, history of tumor or malignancy, or received propofol for indication other than migraine pain relief
- Matching criteria: Age at the time of presentation ± 1 year, sex, and pain score on the NRS ± 1 at initiation of IV therapy
- Sample size: Intended sample size of 51 patients (17 cases matched to 34 controls), assuming an effect size of 40% to achieve a power of 80% at an alpha of 0.05, with 2:1 randomization
- Statistical analysis: Descriptive statistics for demographic data, comparison statistics using the Mann-Whitney U test the Fisher exact test






Acute Treatment of Migraine Pain in the Pediatric Emergency Department: Propofol versus Standard Therapy

Results

Table 1. Patient Characteristics				
	Cases N=11	Controls N=11		
Age, yrs – mean (SD)	14.5 (1.8)	14.4 (1.7)		
Female, n (%)	8 (73)	8 (73)		
Weight, kg – mean (SD)	63.8 (16.6)	56.2 (8.9)		
Family history of migraine, n (%)	5 (46)	5 (46)		
Prior diagnosis of migraine, n (%)	7 (64)	6 (55)		
Daily migraine prophylaxis, n (%)	4 (36)	4 (36)		
Nortriptyline, n (%)	1 (9)	1 (9)		
Flunarizine, n (%)	0 (0)	1 (9)		
Gabapentin, n (%)	1 (9)	0 (0)		
Coenzyme Q10, n (%)	2 (18)	1 (9)		
Magnesium, n (%)	0 (0)	1 (9)		
Riboflavin, n (%)	2 (18)	1 (9)		
Headache duration, day – median (IQR)	7 (7-7.8)	0.4 (0.2-0.7)		
Abortive medications prior to ED, n (%)	7 (64)	9 (82)		
Physical symptoms, n (%)	9 (82)	10 (91)		
Photophobia, n (%)	8 (73)	8 (73)		
Phonophobia, n (%)	6 (55)	4 (36)		
Nausea, n (%)	3 (27)	9 (82)		
Vomiting, n (%)	0 (0)	2 (18)		
Migraine therapy prior to propofol, n (%)	9 (82)	N/A		

Figure 1. Abortive Medications Tried Prior to ED





Results				
Fig	ure 2. I	Post-IV Abor		
Time (min)	1000			
	900			
	800			
	700			
	600			
	500			
	400			
	300			
	200			
	100			
	0			

Table 2. Effectiveness

Post-IV Abortive Thera Score ≤4, n (%)

Total ED LOS, min – n

Rebound Headache, r


Admitted to Hospital, r

Adverse Drug Events, **CNS** Depression

Conclusions

- total ED LOS
- migraine





and Safety			
	Cases N=11	Controls N=11	p value
apy NRS Pain	7 (64)	9 (82)	0.43
median (IQR)	644 (411-987)	412 (299-515)	0.08
n (%)	2 (18)	1 (9)	
n (%)	0 (0)	0 (0)	
s, n (%) n (Naranjo = 3)	1 (9)	0 (0)	

Wide variation in case cohort post-IV abortive therapy ED LOS and

Case cohort appeared to have presented to ED with more refractory